Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of $0.73, $0.97 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $20.11 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.